Establishment Labs (NASDAQ:ESTA) PT Set at $29.00 by Wells Fargo & Co

Share on StockTwits

Establishment Labs (NASDAQ:ESTA) has been given a $29.00 price target by stock analysts at Wells Fargo & Co in a research report issued to clients and investors on Friday, TipRanks reports. The firm presently has a “buy” rating on the stock. Wells Fargo & Co‘s price target would suggest a potential upside of 26.03% from the company’s current price.

Several other analysts have also issued reports on ESTA. ValuEngine lowered Intersect ENT from a “buy” rating to a “hold” rating in a research note on Monday, June 3rd. BTIG Research restated a “buy” rating and issued a $40.00 target price on shares of Establishment Labs in a research note on Thursday, May 16th. Finally, Stephens set a $12.00 target price on Glu Mobile and gave the company a “buy” rating in a research note on Thursday, June 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $35.20.

Shares of ESTA traded up $0.57 during mid-day trading on Friday, hitting $23.01. The stock had a trading volume of 76,206 shares, compared to its average volume of 69,979. The company has a market capitalization of $469.61 million and a price-to-earnings ratio of -20.54. The stock’s fifty day moving average price is $22.39. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.10 and a current ratio of 5.54. Establishment Labs has a 52 week low of $20.05 and a 52 week high of $30.70.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Wednesday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.13). The firm had revenue of $20.78 million during the quarter, compared to the consensus estimate of $18.50 million. Establishment Labs had a negative net margin of 37.74% and a negative return on equity of 68.22%. As a group, research analysts predict that Establishment Labs will post -1.94 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Pura Vida Investments LLC raised its stake in shares of Establishment Labs by 38.3% during the 4th quarter. Pura Vida Investments LLC now owns 287,399 shares of the company’s stock valued at $7,880,000 after purchasing an additional 79,517 shares during the period. Nantahala Capital Management LLC raised its stake in shares of Establishment Labs by 148.0% during the 4th quarter. Nantahala Capital Management LLC now owns 495,958 shares of the company’s stock valued at $13,599,000 after purchasing an additional 295,958 shares during the period. Finally, RTW Investments LP raised its stake in shares of Establishment Labs by 9.3% during the 4th quarter. RTW Investments LP now owns 848,058 shares of the company’s stock valued at $22,740,000 after purchasing an additional 72,249 shares during the period. Institutional investors own 25.77% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Further Reading: What causes a recession?

Analyst Recommendations for Establishment Labs (NASDAQ:ESTA)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.